Evaluation of CA- 125 as a prognostic marker in patients with Non-Hodgkin’s lymphoma
Journal Title: International Journal of Medical and Health Research - Year 2017, Vol 3, Issue 4
Abstract
Background: Non-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers that includes all types of lymphoma except Hodgkin's lymphomas. CA-125 is a protein that in humans is encoded by the MUC16 gene. The present study was conducted to assess the role of CA- 125 in patients suffering from non- Hodgkin lymphoma. Materials &Methods: This study was conducted from year 2011 to 2015 on the patients visiting a tertiary care hospital in north India. It included 110 patients suffering from Non-Hodgkin’s lymphoma. Patients were divided into two groups. Group I with CA-125 level < 35 U/ml and group II with CA-125 level > 35 U/ml. Complete blood count (CBC) and levels of urea, creatinine, calcium, total bilirubin, lactate dehydrogenase (LDH), aspartate transaminase (AST), and alanine transaminase (ALT) were collected. Viral markers such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-cell lymphoma virus (HTLV-I) were also evaluated for some of the patients. Serum CA-125 level was measured using chemiluminescence. The International Prognostic Index (IPI) was calculated. Staging of NHL was also assessed. Results: Out of 110 patients, group I (CA- 125 level <35 U/ml) had 60 patients and group II (CA- 125 level >35 U/ml) had 50 patients. Relapse rate in group I and group II was 15.8% and 33.4% respectively. The mortality rate in group I was 10% and in group II was 28%. The difference was significant (P <0.05). Group I had 34 males and 26 females and group II had 28 males and 22 females. The difference was non – significant (P = 0.25). 60% in group I and 25% in group II had low IPI score. 8.5% in group I and 12.6% in group II had high IPI score. The difference was significant (P < 0.05). 55% in group I and 25% in group II had stage I, 33% in group I and 37% in group II had stage II, 10% in group I and 24% in group II had stage III and 2% in group I and 14% in group II had stage IV. The difference was significant (P < 0.05). Conclusion: CA- 125 is a biomarker can be useful in evaluating prognosis in Non Hodgkin lymphoma patients and their response to treatment. It is a cost effective and non-invasive marker.
Authors and Affiliations
Dr. Sanjeev Garg, Dr. Bela Goyal
Keywords
Related Articles
- EP ID EP584922
- DOI -
- Views 121
- Downloads 0
Comparison of different doses of aspirin on renal function in elderly patients
Low dose aspirin has been reported to be a risk factor of hyperuricemia. Hence this study was planned to study the effect of low dose aspirin compromises renal function, and if so, to alert practicing physicians on the n...
Variations in renal arteries in human cadaver
Renal arteries supply blood to the kidneys. Over 2 million people dies every year out of kidney failures. Urologist has taken huge interests in the study of variations of renal arteries. Out of 8 sampled unpreserved cada...
Bilateral anterior shoulder fracture dislocation in a cycling athlete: A case report
Bilateral anterior fracture dislocation of the shoulder is very rare. We report a case of traumatic bilateral anterior dislocation of shoulders. We discuss the mechanism of the dislocation which is unusual and the treatm...
Neonatal gynecomastia complicated by morphine induced hyperprolactinemia
Neonatal gynecomastia is defined as “benign proliferation of glandular breast tissue”. It is considered to be a physiological variant seen in approximately 70% of infants in the first few months. Hyperprolactinemia & neo...
A histopathological study of lesions of nasal cavity and para nasal sinuses
Background: Lesions of nasal cavity are quite common. It can be neoplastic and non-neoplastic. Diseases of the nasal cavity include viral, bacterial and fungal infections, nasal cavity tumors as well as inflammations of...